register

News & Trends - Medical Technology

Icon Group and Varian collaborate to tackle the growing cancer burden

Health Industry Hub | March 31, 2021 |
[Total: 1    Average: 5/5]

MedTech News: Icon Group has signed an agreement with Varian Medical Systems investing in 30 Varian linear accelerators and associated treatment software to help tackle the growing global cancer burden.

This agreement further strengthens the global partnership between Varian and Icon Group, together increasing access to care across regional and underserved areas in Australia and Asia.

The order is comprised of a variety of Varian linear accelerators and software including Halcyon system, TrueBeam and HyperArc. These systems will be installed in new and existing Icon cancer centres in Australia to increase capacity and broaden patient access, as well as in cancer centres in Singapore and Mainland China.

Icon Group CEO, Mark Middleton said this investment represents the group’s commitment to addressing the increasing global cancer burden.

“Icon has come out of the worst of COVID strong and this significant investment in radiation technology signifies Icon’s inexhaustible drive to increase access to cancer care and bring more care to people who need it most.”

The 30 new linacs will be installed across a range of Icon centres, including existing cancer centres to increase capacity, new Australian regional centres and centres in Singapore and Mainland China. There are current concerns the reduction in cancer diagnosis due to COVID-19 lockdowns will cause a ‘tsunami of cancer’ which will result in further demand for treatment facilities. Installing Varian technology into Mainland China is particularly important with large populations currently without access to advanced radiation therapy treatments, often resulting in radical surgeries with poorer outcomes, or patients deciding to forego treatment all together.

“We are proud of our global partnership with Varian which continues to help meet our long-term goal of increasing access to cancer care to regional and rural Australia and deliver a world-class level of care to more communities across Asia. Together we are bringing new standards of care to the field of radiation oncology and paving the path to a world where cancer is no longer a burden; where people have every opportunity to fight cancer no matter where they live.”

Icon continues to play a paramount role in the development of radiation oncology treatments and has been an early adopter of Varian technologies over the years, including the first in Australasia to install the Varian Halcyon radiotherapy system and first in Australia to install and treat with HyperArc technology – benefitting patients with multiple tumours in the brain.

Icon Group is also a member of the Varian Adaptive Intelligence Consortium, alongside other peak international bodies, to collaboratively develop clinical and technical aspects of Ethos therapy and wider radiation therapy treatments and techniques that will continue to evolve cancer care.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]

More


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]

More


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]

More